10-Q: BioCardia Reports Q1 2025 Results, Cautions About Going Concern Status

BioCardia's Q1 2025 results reveal a net loss and raise concerns about the company's ability to continue as a going concern without additional funding.

Summary

• BioCardia, Inc. reported its financial results for the first quarter of 2025.
• The company is focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases.
• BioCardia's lead therapy, CardiAMP, is in clinical trials for ischemic heart failure and refractory angina.
• The company's Q1 2025 revenue was $0, compared to $55,000 in Q1 2024.
• Research and development expenses increased to $1.53 million from $1.241 million year-over-year.
• Selling, general, and administrative expenses rose to $1.196 million from $1.089 million year-over-year.
• The net loss for Q1 2025 was $2.712 million, or $0.59 per share, compared to a net loss of $2.267 million, or $1.35 per share, in Q1 2024.
• As of March 31, 2025, BioCardia had $949,000 in cash and cash equivalents.
• Management believes that current cash resources are insufficient to fund planned expenditures beyond July 2025.
• The company plans to raise additional capital through debt and equity arrangements.
• There is substantial doubt about the company's ability to continue as a going concern beyond one year from the date the financial statements are issued.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's net losses, declining revenue, limited cash runway, and the going concern uncertainty. While there are some positive clinical trial developments, the financial challenges outweigh them.

Positives

• CardiAMP Cell Therapy has received Breakthrough Device Designation from the FDA.
• Two-year results from the CardiAMP HF trial demonstrated increased survival, decreased cardiac events, and improved quality of life for treated patients.
• Patient enrollment has commenced in the CardiAMP HF II Phase 3 trial.
• The Data Safety Monitoring Board recommended that the CardiALLO study proceed as designed.
• FDA approved the Morph-DNA product family for market release in August 2024.

Negatives

• The company reported a net loss of $2.712 million for Q1 2025.
• Revenue decreased from $55,000 in Q1 2024 to $0 in Q1 2025.
• The company's cash and cash equivalents of $949,000 as of March 31, 2025, are not sufficient to fund planned expenditures beyond July 2025.
• There is substantial doubt about the company's ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• Failure to obtain regulatory approval for therapeutic candidates could adversely affect the company's financial position.
• Clinical trials may not be successful, and results may not support regulatory approval.
• The company faces competition from other companies developing therapies for cardiovascular and pulmonary diseases.
• The company's securities could be delisted from the Nasdaq if it does not regain compliance with continued listing requirements.
• Future equity offerings may result in dilution for existing shareholders.

Future Outlook

The company plans to raise additional capital to fund its operations and continue the development of its therapeutic candidates. Management expects operating losses and negative cash flows to continue through at least the next several years. The company intends to share the two-year data from the CardiAMP HF trial with both the FDA and Japan Pharmaceuticals and Medical Devices Agency and align on pathways to make CardiAMP available for physicians and their patients.

Management Comments

• Management expects operating losses and negative cash flows to continue through at least the next several years.
• Management believes that the cash and cash equivalents of $949,000 as of March 31, 2025, together with gross proceeds of $775,000 from the private placement in April 2025 and $234,000 from ATM offerings from April 1, 2025 to May 13, 2025 are not sufficient to fund planned expenditures and meet obligations beyond July 2025.

Industry Context

BioCardia operates in the competitive field of regenerative medicine, specifically focusing on cell therapies for cardiovascular and pulmonary diseases. The company's success depends on the clinical trial outcomes of its CardiAMP and CardiALLO programs, regulatory approvals, and its ability to secure funding. The industry is characterized by high research and development costs, lengthy regulatory processes, and the need for innovative delivery systems like BioCardia's Helix system.

Comparison to Industry Standards

• BioCardia's focus on cell therapies for cardiovascular diseases aligns with industry trends, with companies like Mesoblast and Vericel also developing cell-based therapies.
• The CardiAMP HF II trial's composite endpoint is similar to those used in other heart failure trials, such as those conducted by Novartis with Entresto.
• The company's reliance on equity financing is common among clinical-stage biotech companies, but the need for additional funding raises concerns about dilution.
• The company's cash runway is shorter than some of its peers, which may put pressure on its ability to execute its clinical development plans.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees face uncertainty due to the company's financial challenges and potential need to reduce operating expenses.
• Patients may benefit from the development of new cell therapies, but the company's financial situation could delay or halt clinical trials.
• Suppliers and creditors face increased risk of non-payment due to the company's limited cash resources.

Next Steps

• Share two-year data from the CardiAMP HF trial with the FDA and Japan Pharmaceuticals and Medical Devices Agency.
• Align with regulatory agencies on pathways to make CardiAMP available for physicians and patients.
• Continue patient enrollment in the CardiAMP HF II Phase 3 trial.
• Prepare primary results of the chronic myocardial ischemia roll-in cohort for publication and presentation.
• Fund later development of CardiALLO through nondilutive grant applications and partnering.
• Transition all procedures using the Helix transendocardial delivery system to the new FDA cleared Morph DNA platform.
• Submit a plan to Nasdaq to regain compliance with the Nasdaq Listing Rules.
• Raise additional capital through debt and equity arrangements.

Key Dates

Keywords

BioCardia, CardiAMP, cell therapy, heart failure, ischemic heart failure, refractory angina, clinical trials, financial results, going concern, capital raise, Helix, Morph DNA